Plain-English translation of NCT07570862 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called , which is made from specially engineered immune cells, for people with severe lupus that has damaged the kidneys and hasn't improved with other medications. The treatment involves a single infusion of these cells after preparing the body with a conditioning medication. Researchers want to see if this approach can reduce kidney damage and lupus symptoms.
Many people with severe lupus that affects the kidneys don't get better even after trying two or more standard treatments. This trial exists to find out whether this new cell-based therapy can help patients whose disease has been hard to control with conventional medicines.
You likely qualify if…
You likely don't qualify if…
After a screening visit to confirm you qualify, you will receive a conditioning medication called bendamustine, followed by a single infusion of the new cell therapy. You will have follow-up visits and blood tests at regular intervals over 24 months to monitor how well the treatment works and watch for any side effects. After these 24 months, you will continue in long-term follow-up visits for up to 15 years to ensure your safety and track your recovery.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
United States